biostudies-literatureDeng TNational Natural Science Foundation of ChinaMinistry of Science and Technology of the People's Republic of China6839-6848https://www.ebi.ac.uk/biostudies/studies/S-EPMC9510068biostudies-literatureUnknown40(47)The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drastically changed our way of life and continues to have an unmitigated socioeconomic impact across the globe. Research into potential vaccine design and production is focused on the spike (S) protein of the virus, which is critical for virus entry into host cells. Yet, whether the degree of glycosylation in the S protein is associated with vaccine efficacy remains unclear. Here, we first optimized the expression of the S protein in mammalian cells. While we found no significant discrepancy in purity, homogeneity, or receptor binding ability among S proteins derived from 293F cells (referred to as 293F S-2P), 293S GnTI- cells (defective in N-acetylglucosaminyVaccineCharacterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation.PMC95100682020YFC08426008204103882001756Xu LDeng TZhu YZhang JGu YHong JZhang HYuan QChen GLin YZheng QWu DYu HZhang TLi SLi TZhao QXia NFang QChen YSun HWang YGao SfalseCharacterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation.The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drastically changed our way of life and continues to have an unmitigated socioeconomic impact across the globe. Research into potential vaccine design and production is focused on the spike (S) protein of the virus, which is critical for virus entry into host cells. Yet, whether the degree of glycosylation in the S protein is associated with vaccine efficacy remains unclear. Here, we first optimized the expression of the S protein in mammalian cells. While we found no significant discrepancy in purity, homogeneity, or receptor binding ability among S proteins derived from 293F cells (referred to as 293F S-2P), 293S GnTI- cells (defective in N-acetylglucosaminy2022-01-01T00:00:00Z2022 Nov2025-04-21T23:39:45.304Z2025-02-18T23:58:21.004ZS-EPMC95100683625322010.1016/j.vaccine.2022.09.057